Get access to our best features
Get Started
SubscribeLogin
Get access to our best features
Get Started
Published

NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_

Summary by modernreaders.com
On January 10, 2025, NextCure, Inc. (NASDAQ: NXTC) made a significant announcement through a press release, indicating the dosing of the first patient in the Phase 1 study of LNCB74. LNCB74 represents a B7-H4-targeting antibody-drug conjugate (ADC), strategically designed as a therapeutic approach for the treatment of multiple cancers. Dr. Udayan Guha, Senior Vice President of Clinical & Translational Development at NextCure, expressed, “Dosing …
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

CancerCancer
Rockville, MarylandRockville, Maryland
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2025 Snapwise Inc
News
For You
Search
BlindspotLocal